Evidence map›Paper›PMID 40500766›Full record

ArticleCost effectiveness and resource allocation : C/E2025

Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study in 2021.

Tianqi Sun, Tianfu Yu, Pengcheng Liu

Abstract read
In one paragraph

Article in Cost effectiveness and resource allocation : C/E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tianqi SunSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Tianfu YuDepartment of Neurosurgery, The Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, China.
Pengcheng LiuSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China. liupcmail@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdiopathic epilepsy is a serious neurological disorder that can lead to premature death and severe disability. We aimed to assess the global burden of idiopathic epilepsy, to provide a comprehensive understanding of the current dynamics and trends in idiopathic epilepsy, and to gain insight into its epidemiological attributes.

methodsThis study assessed the global, regional, and national impact of idiopathic epilepsy through incidence and disability-adjusted life year (DALY) based on the Global Burden of Disease Study 2021 (GBD 2021). After statistically summarizing the global incidence rates and disability-adjusted life years (DALYs), we performed Estimating Average Percent Change (EAPC) correlation analyses and Joinpoint regression analyses to further derive global trends in idiopathic epilepsy incidence rates and DALYs. Furthermore, through decomposition analysis, we determined which factors significantly influence the change in incidence and DALYs and the extent of their contribution. In addition, this study quantified the disparities in the burden of idiopathic epilepsy across countries through cross-country social inequality analyses, and finally predicted the future burden of idiopathic epilepsy based on Bayesian Age-Period-Cohort Model (BAPC).

resultsFrom 1990 to 2021, the incidence of idiopathic epilepsy increased generally, whereas DALY decreased. In terms of age and gender, the burden of idiopathic epilepsy is more severe in children and older age groups, with males bearing a higher burden than females. In terms of geographical distribution, the incidence was significantly higher in high Socio-Demographic Index (SDI) regions, while the burden of idiopathic epilepsy was heavier in low SDI areas. Decomposition analyses showed that the increase in incidence of idiopathic epilepsy and DALY in high SDI regions was mainly driven by epidemiological changes, whereas the increase in low SDI areas was more due to population growth. Cross-country social inequality analyses showed that despite improvements in the burden of idiopathic epilepsy, the burden and inequalities in low SDI countries remains significant. Projections indicated an increase in the incidence of idiopathic epilepsy globally, particularly in the 85 + age group, while global DALY was anticipated to continue declining.

conclusionsAlthough global health is improving in line with population growth and age structure, the burden of idiopathic epilepsy remains significant. This study provides an important basis for prevention and care strategies for idiopathic epilepsy in different regions. Future work should focus on integrating idiopathic epilepsy into public health priorities, promoting effective measures, and narrowing treatment gaps.

Indexed as

Disability-adjusted life yearsEpilepsyGlobal burden of diseaseIncidenceSocio-demographic index

Identifiers

PMID40500766
PMCPMC12160428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.